北京大学人民医院2009～2011年口服血脂调节药门诊用药情况分析

Analysis of the application of antihyperlipidemics in outpatients of Peking University People's Hospital from 2009 to 2011

目的通过分析北京大学人民医院2009～2011年门诊血脂调节药物使用情况,为临床合理用药提供参考。方法基于销售数量、金额排序及频度等指标的分析,采用回顾性研究方法,对北京大学人民医院2009～2011年门诊血脂调节药物的使用情况进行统计分析。结果北京大学人民医院门诊血脂调节类药物销售数量及销售金额逐年上升,2010年和2011年门诊血脂调节药的销售量比2009年分别增长了37.3%和60.3%。其中,羟甲基戊二酰辅酶A(HMG-CoA)还原酶抑制剂销售额最高,其他类药物用药量较小。结论 HMG-CoA还原酶抑制剂在北京大学人民医院门诊血脂调节药物销售中占主导地位。

Objective To analyze the use of antihyperlipidemies in outpatients of Peking University People＇s Hospital during 2009-2011 and provide reference for rational drug use in clinic. Methods Based on the sales amount, con- mmption sum and DDDs of antihyperlipidemics, the use of antihyperlipidemics in our hospital from 2009 to 2011 were analyzed retrospectively. Results The sales amount and consumption sum of antihyperlipidemics used in outpatient of our hospital increased year by year. The sales amount of antihyperlipidemics increased by 37.3% in 2010 and 60.3% in 2011 compared with that in 2009. The consumption sum of HMG-CoA reductase inhibitor ranked the first in anti- hypedipidemics. Conclusion Among the antihyperlipidemics used in our hospital, the consumption of HMG-CoA re- ductase inhibitor takes a leading place.